Novo Nordisk A/S (NYSE:NVO) Shares Bought by Iams Wealth Management LLC

Iams Wealth Management LLC raised its position in Novo Nordisk A/S (NYSE:NVO) by 39.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 23,772 shares of the company’s stock after buying an additional 6,769 shares during the period. Iams Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $2,045,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Natixis Advisors LLC boosted its holdings in Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after buying an additional 80,070 shares during the last quarter. Norman Fields Gottscho Capital Management LLC boosted its holdings in Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after buying an additional 19,870 shares during the last quarter. Versant Capital Management Inc acquired a new stake in Novo Nordisk A/S in the 4th quarter worth about $86,000. Talbot Financial LLC purchased a new position in Novo Nordisk A/S in the 4th quarter worth approximately $4,066,000. Finally, Zions Bancorporation N.A. lifted its stake in Novo Nordisk A/S by 57.0% in the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after purchasing an additional 6,726 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on NVO. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $85.51 on Wednesday. The company has a fifty day simple moving average of $94.75 and a two-hundred day simple moving average of $114.02. The company has a market cap of $383.73 billion, a price-to-earnings ratio of 27.70, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.